Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density

Anti-malarial pre-erythrocytic vaccines (PEV) target transmission by inhibiting human infection but are currently partially protective. It has been posited, but never demonstrated, that co-administering transmission-blocking vaccines (TBV) would enhance malaria control. We hypothesized a mechanism that TBV could reduce parasite density in the mosquito salivary glands, thereby enhancing PEV efficacy. This was tested using a multigenerational population assay, passaging Plasmodium berghei to Anopheles stephensi mosquitoes. A combined efficacy of 90.8% (86.7-94.2%) was observed in the PEV +TBV antibody group, higher than the estimated efficacy of 83.3% (95% CrI 79.1-87.0%) if the two antibodies acted independently. Higher PEV efficacy at lower mosquito parasite loads was observed, comprising the first direct evidence that co-administering anti-sporozoite and anti-transmission interventions act synergistically, enhancing PEV efficacy across a range of TBV doses and transmission intensities. Combining partially effective vaccines of differing anti-parasitic classes is a pragmatic, powerful way to accelerate malaria elimination efforts.

[1]  R. Sinden,et al.  Heterogeneity in patterns of malarial oocyst infections in the mosquito vector , 1993, Parasitology.

[2]  D. Webster,et al.  Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. , 2005, The Journal of infectious diseases.

[3]  R. Sinden,et al.  A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity , 2011, PloS one.

[4]  B. Genton,et al.  A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.

[5]  V. Nussenzweig,et al.  Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite's cell traversal activity. , 2012, Journal of immunological methods.

[6]  P. Gething,et al.  Transmission-blocking interventions eliminate malaria from laboratory populations , 2013, Nature Communications.

[7]  T. Bousema,et al.  An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines , 2016, Malaria Journal.

[8]  P. Walker,et al.  Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. , 2016, The Lancet. Global health.

[9]  S. Hoffman,et al.  The march toward malaria vaccines. , 2015, Vaccine.

[10]  J. Griffin,et al.  Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts , 2017, PLoS pathogens.

[11]  T. Theander,et al.  Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. , 2017, Vaccine.

[12]  A. Hill,et al.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine , 2017, Scientific Reports.

[13]  R. Rosenberg.  Malaria: some considerations regarding parasite productivity. , 2008, Trends in parasitology.

[14]  M. Fay,et al.  Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.

[15]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[16]  A. Nicosia,et al.  Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum , 2015, Scientific Reports.

[17]  Peter D. Crompton,et al.  Malaria Vaccines: Moving Forward After Encouraging First Steps , 2015, Current Tropical Medicine Reports.

[18]  P. Gething,et al.  Lead Clinical and Preclinical Antimalarial Drugs Can Significantly Reduce Sporozoite Transmission to Vertebrate Populations , 2014, Antimicrobial Agents and Chemotherapy.

[19]  A. Nicosia,et al.  A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS , 2014, PloS one.

[20]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[21]  Gareth O. Roberts,et al.  A General Framework for the Parametrization of Hierarchical Models , 2007, 0708.3797.

[22]  M. Fay,et al.  Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults , 2016, PloS one.

[23]  Martin Walker,et al.  Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection , 2013, eLife.

[24]  T. Lefèvre,et al.  Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations , 2017, Scientific Reports.

[25]  R. Cibulskis,et al.  World Malaria Report 2013 , 2014 .

[26]  D. Kaslow,et al.  Crystallization of an intact monoclonal antibody (4B7) against Plasmodium falciparum malaria with peptides from the Pfs25 protein antigen. , 1994, Acta crystallographica. Section D, Biological crystallography.

[27]  O. Gaye,et al.  The Quantity and Quality of African Children's IgG Responses to Merozoite Surface Antigens Reflect Protection against Plasmodium falciparum Malaria , 2009, PloS one.

[28]  A. Nicosia,et al.  Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults , 2015, Science Translational Medicine.

[29]  Lili Zhao,et al.  Current Trends in Bayesian Methodology with Applications , 2016 .

[30]  Mollie E. Brooks,et al.  Generalized linear mixed models: a practical guide for ecology and evolution. , 2009, Trends in ecology & evolution.

[31]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[32]  A. Ghani,et al.  The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection , 2013, PloS one.

[33]  A. Thomas,et al.  Humoral Immune Responses to a Single Allele PfAMA1 Vaccine in Healthy Malaria-Naïve Adults , 2012, PloS one.

[34]  R. Sinden,et al.  Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. , 2012, International journal for parasitology.

[35]  A. Thomas,et al.  Humoral Immune Responses to a Single Allele PfAMA1 Vaccine in Healthy Malaria-Naı̈ve Adults , 2017 .

[36]  M. Betancourt,et al.  Hamiltonian Monte Carlo for Hierarchical Models , 2013, 1312.0906.

[37]  L. Rénia,et al.  Pre-erythrocytic antigens of Plasmodium falciparum: from rags to riches? , 2003, Trends in parasitology.

[38]  M. Rowland,et al.  Mosquito Nets Treated with a Mixture of Chlorfenapyr and Alphacypermethrin Control Pyrethroid Resistant Anopheles gambiae and Culex quinquefasciatus Mosquitoes in West Africa , 2014, PloS one.

[39]  Tyler J. VanderWeele,et al.  A Tutorial on Interaction , 2014 .

[40]  R. Sauerwein,et al.  Malaria vaccines getting close to clinical reality. , 2015, Vaccine.

[41]  A. Wallqvist,et al.  The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity , 2016, Malaria Journal.

[42]  Yuming Guo,et al.  The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.

[43]  R. Sinden,et al.  Progression of Plasmodium berghei through Anopheles stephensi Is Density-Dependent , 2007, PLoS pathogens.

[44]  A. Blagborough,et al.  A novel model fitted to multiple life stages of malaria for assessing efficacy of transmission-blocking interventions , 2017, Malaria Journal.